Download PDFPDF

Randomised controlled trial
Semaglutide is non-inferior to placebo for cardiovascular outcomes in patients with type 2 diabetes
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address